Avid Bioservices, Inc. (NASDAQ: NASDAQ:CDMO) reported its financial results for the first quarter of fiscal year 2025 on September 9, 2024. The company, a dedicated contract development and manufacturing organization (CDMO), experienced a revenue increase of 6% to $40.2 million, primarily driven by higher process development revenues.
Despite this growth, Avid Bioservices faced a net loss of $5.5 million and saw a rise in SG&A expenses. CEO Nick Green highlighted the record backlog of $219 million from new project agreements and remained optimistic about the company's growth prospects.
Key Takeaways
- Avid Bioservices' revenues rose to $40.2 million, marking a 6% increase.
- Gross profit improved to $5.7 million with a 14% margin.
- SG&A expenses surged by 30% due to higher compensation and consulting fees.
- The company reported a net loss of $5.5 million, a larger deficit than the previous year.
- Adjusted EBITDA stood at $3 million, with a decrease in cash and cash equivalents to $33.4 million.
- Avid secured $66 million in new project agreements, contributing to a record backlog.
- CEO Nick Green discussed the company's strategy with large pharma clients and the cell and gene therapy sector's challenges.
Company Outlook
- Avid Bioservices anticipates growth in adjusted EBITDA and margins, with a potential 40% to 60% increase in incremental revenue.
- The company expects to fill remaining capacity to drive revenue growth and improve margins.
- Avid remains optimistic about the future, despite a long sales cycle with large pharma clients and challenges in the cell and gene therapy sector.
Bearish Highlights
- Net loss widened to $5.5 million from $2.1 million in the same quarter last year.
- SG&A expenses increased significantly by 30%.
- Cash and cash equivalents decreased from $38.1 million to $33.4 million.
Bullish Highlights
- Record backlog of $219 million due to securing $66 million in new project agreements.
- Gross profit margin improved from 11% to 14%.
- The majority of new projects came from new customers, indicating a diversifying client base.
Misses
- The company missed on net earnings, reporting a larger loss compared to the previous year.
- A decline in revenue contribution from key customer Halozyme (NASDAQ:HALO), from over half in fiscal 2023 to about a third in fiscal 2024.
Q&A Highlights
- CEO Nick Green addressed no significant changes in demand from large pharma clients and the steady progression of the company's large pharma strategy.
- Demand for cell and gene therapy remains behind traditional biologics, with no significant recovery observed.
- The BIOSECURE Act may influence approximately half of the current pipeline from China, but its full impact is unclear.
- The upcoming quarter will include a shutdown for facility maintenance, although it may not be as extensive as in previous years.
- Despite a decline in revenue from Halozyme, the relationship remains strong, and Avid Bioservices aims to grow and diversify its customer base.
Avid Bioservices, Inc. (NASDAQ: CDMO) has presented a combination of achievements and challenges in its Q1 FY 2025 earnings call. While the company has succeeded in securing new agreements and increasing its revenue, it has also faced a growing net loss and rising operational costs. The management team has expressed confidence in their strategy and the company's future, underpinned by a record backlog and a focus on expanding customer relationships. The financial community will be watching closely to see how Avid Bioservices navigates the dynamic landscape of the biopharmaceutical industry in the coming quarters.
Full transcript - Avid Bioservices Inc (CDMO) Q1 2025:
Operator: Good day and thank you for standing by. Welcome to the Avid Bioservices First Quarter Fiscal Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today. Tim, please go ahead.
Tim Brons: Thank you. Good afternoon and thank you for joining us. On today's call, we have Nick Green, President and CEO; Dan Hart, Chief Financial Officer; and Matt Kwietniak, Avid's Chief Commercial Officer. Today, we will be providing an overview of Avid Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31, 2024. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, September 9, 2024, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release includes a discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations on our corporate website, avidbio.com. With that, I will turn the call over to Nick Green, Avid's President and CEO.
Nick Green: Thank you, Tim, and thank you to everybody participating today via webcast. Building on the momentum from quarter four fiscal '25 is off to a good start and we are delighted to be reporting what I can only describe as a solid first quarter. We are encouraged by the strong revenues and new business signings which continue to build our backlog and improve our margins. Matt and I will provide additional details on business development and operations for the period following an overview of our first quarter fiscal '25 financial results. And for that, I'll turn the call over to Dan.
Dan Hart: Thank you, Nick. Before I begin, in addition to the brief financial overview, I'll provide on the call today, additional details on our financial results are included in our press release issued prior to this call and in our Form 10-Q, which was filed today with the SEC. I'll now provide an overview of our financial results from operations for the quarter ended July 31, 2024. Revenues for the first quarter of fiscal 2025 were $40.2 million, representing a 6% increase as compared to revenues of $37.7 million recorded in the same prior year period. The increase was primarily attributed to an increase in process development revenues during the period. Gross profit for the first quarter of fiscal 2025 was $5.7 million, 14% gross margin compared to $4.1 million, or 11% gross margin, in the first quarter of fiscal 2024. The increase in gross profit for the first quarter ended July 31, 2024, compared to the same prior year period was primarily driven by the increased revenues and lower material costs used for customer programs, partially offset by increases in compensation and benefit-related expenses, facility manufacturing and other related expenses and depreciation expense. SG&A expenses for the first quarter of fiscal 2025 were $8.2 million, an increase of 30% compared to $6.3 million recorded in the first quarter of fiscal 2024. The increase in SG&A for the first quarter ended July 31, 2024, compared to the same prior year period was primarily due to increases in compensation and benefit-related expenses and audit, legal, and other consulting fees. During the first quarter of fiscal 2025, the company's net loss was $5.5 million or $0.09 per basic and diluted share, compared to a net loss of $2.1 million or $0.03 per basic and diluted share for the first quarter of fiscal 2024. For the first quarter of fiscal 2025, the company had an adjusted EBITDA of $3 million. Our cash and cash equivalents on July 31, 2024, were $33.4 million, compared to $38.1 million on April 30, 2024. This concludes my financial overview. I'll now turn the call over to Matt, for an update on commercial activities during the quarter.
Matt Kwietniak: Thanks, Dan. Q1 2025 was a highly productive quarter for our team as we signed $66 million net in new project agreements and ended the quarter with a backlog of $219 million. The backlog sets another record high for the company and the net new wins are the highest since the third quarter of fiscal 2023. We are also pleased with the composition of these signings as a significant majority are projects with new customers, including the addition of another large pharma customer. As we've discussed previously, the sales cycle with big pharma companies is generally long and evolved. I am very proud of our team and the professionalism they showed in showcasing Avid's exceptional service, skill, and quality throughout this process. As we deliver for our new large pharma clients, we expect to capitalize on the reputation we build and increase our exposure to more large pharma over time. Our new signings also have a good mix of early and late-stage programs, though we continue to be weighted more toward late stage. During the first quarter, we were successful in bringing in programs at both ends of the development spectrum. As we've discussed on prior earnings calls, a mix of early and late-stage programs provides a balance between near and longer-term revenues, as well as the opportunity to grow with new and existing customers. With respect to our newest late-stage programs, we are very pleased to report that two of our PPQ programs, one of which is a Phase 3 program advancing towards commercialization, and the other is a commercially approved product currently on the market. As we've discussed in the past, PPQ programs are particularly attractive, as they are a pre-commercialization requirement. And while we caution that the execution of a PPQ campaign is only the beginning of a one to two year journey toward a potential commercial approval and subsequent manufacture, we cannot underestimate the importance that we believe such programs may have in our growth now and in the future as we expect they will drive an increase in revenues, capacity utilization, and ultimately our margins. In conclusion, I am extremely pleased with our performance during the first quarter of fiscal 2025, and we are looking forward to the balance of the year with great optimism. This concludes my overview of commercial activities. I will now turn the call back over to Nick for an update on operations and other achievements during the quarter.
Nick Green: Thanks, Matt. During the quarter, we achieved several important high marks for the company, including strong revenues, new business signings, both of which continue to drive a robust backlog and improving margins. The investments of the last few years in infrastructure, facilities, capacity, and the expansion of our capabilities continue to attract new business and a wider range of opportunities. Our new infrastructure and organization are now better equipped to support the needs of large pharma with the same excellence and agility that we provide to smaller biotech companies. And we look forward to the continued diversification of our customer base and our project pipeline with key programs from early stage to commercialization. We're excited that our story has continued to unfold just as we have laid out in the past, and I'd like to thank all my colleagues at Avid Bioservices for their part in executing this strategy. Looking ahead, our primary focus is on filling our remaining capacity. As we continue to sign new business and execute on our backlog, we expect revenues and capacity utilization to increase, generating stronger margins and positioning Avid to achieve strong growth going forward. This concludes my prepared remarks for today, and we can now open the call for questions. Operator?
Operator: [Operator Instructions] One moment for the first question. And our first question today will be coming from Sean Dodge of RBC Capital Markets. Your line is open.
Sean Dodge: Yup. Thanks. Good afternoon. Congratulations on the strong bookings quarter. On those bookings, so Matt mentioned lots of different contributors there, new customers, early-stage stuff, late-stage, and then some stuff progressing towards commercial. I guess, if we think about the mix there and compare it to your current backlog, including these $66 million of new wins, will this accelerate or decelerate your backlog burn rate over the next call it four or five quarters or is the make above this pretty similar to what's already in backlog. So really shouldn't affect backlog conversion, if that makes sense.
Nick Green: Yes, Sean, it does make sense. I don't think it's going to have a dramatic effect, but it is going to be probably slightly more accelerating than decelerating, just due to the fact that we've got, I think a better proportion of early phase clients in the quarter than we have in prior quarters. As you know, the prior quarters were in the high watermark. But I think there was a -- it was nice to see as -- I think, Matt, articulated to see a sort of a nice balance to the signing. So slightly accelerating, but I wouldn't say it was worth being notable in that regard.
Sean Dodge: Okay, great. And then you mentioned two PPQ campaigns you won in the quarter. I guess, any more detail you can share on those. Are these something you took away from another CDMO? Are you going to be serving as a secondary supplier in those cases? And then any detailed bookings you can share on once these things get fully ramped, what they could contribute, kind of roughly in terms of annual revenue?
Nick Green: Yes, we don't really go forward too much in terms of the forecasting to the future revenues, but in terms of where they came from, interestingly, one of them actually is a commercial product that is being outsourced from internal manufacture. So it's already approved, which is quite exciting. So that one probably a little more advanced than most in regard, as I say, it's already on the market. The other one, by virtue of the fact that it is coming in, it's coming in from another CDMO. And in Phase 3, obviously, Phase 1 and Phase 2 have been manufactured somewhere else. So that's kind of, I guess, a win to some degree. No second suppliers as far as I'm aware.
Sean Dodge: Okay. Got it. Thanks and congratulations again.
Nick Green: Thanks very much, Sean. Appreciate it.
Operator: Thank you. One moment for the next question. And our next question will be coming from Jacob Johnson of Stephens. Your line is open.
Unidentified Analyst: Good afternoon, this is [Mac] on for Jacob. Just a few quick questions for me, just on a large pharma strategy, I know, you called out another addition there. But given there's been some noise around large pharma pruning some earlier stage pipelines in recent months. I guess, there is two questions here. Is there any update on how your large pharma strategy is progressing as compared to your internal expectations? And two, any changes in demand from these customers as of late.
Nick Green: I'll answer your second question first, Mac. No changes from them as late. So I think, getting to your point of whether their strategies or issues have changed their demand from us personally, then that wouldn't seem to be the case. I think, in terms of the strategy as a whole, it's one of those strategies that's long and as Matt has alluded to, it's very involved. There's a lot of audits, visits, establishing your reputation, et cetera. I think we're on track for where we'd like to be in general. I think there are some areas we'd like to have moved a little bit quicker from some accounts, but there are other accounts that have developed that we didn't necessarily expect to develop as quick. So on the whole, roughly in line, I'm being in a rather impatient individual though, I would say, I'd always want it to be faster if we could be. I can assure you though, however, that speed is not down to anything that we're not trying to do ourselves.
Unidentified Analyst: I appreciate the color there. And then just quickly on the cell and gene therapy side of things, I think you mentioned last quarter, this is a bit behind traditional biologics demand in terms of coming back. And given your early phase comments, is this still the case or what were you seeing in those end markets?
Nick Green: Yes, I think that still is the case. I certainly, don't see it. I haven't seen it catch up in any way, shape, or form at the moment. I do think the vast majority of the drive is in the mammalian conversations continue to be pretty nicely developing in the cell and gene therapy area. But I wouldn't say that the activity, the funding or what have you is flowing back into that sector yet. So mammalian ahead for sure. I don't think its cell and genes caught up anything from where we were last quarter. We do have some interesting conversations, and hopefully, in the next quarter or two we can start to convert the conversations into orders, but that's kind of where we are at the moment.
Unidentified Analyst: Thank you. I appreciate you taking the questions.
Nick Green: Appreciate it.
Operator: Thank you. One moment for the next question. And our next question will be coming from Matt Hewitt of Craig-Hallum Capital Group. Your line is open.
Matthew Hewitt: Good afternoon. Congratulations on the strong quarter. Maybe first up, and I apologize, the vote was happening right as we were coming on, but the BIOSECURE Act made it to the house floor. I did not hear. But I'm just curious, what's your thoughts are. You know, and I know that your customers don't always call in and say, hey, because of this potential law, we're going to sign up. But I'm just curious if you're seeing any change or any increase in conversations that could possibly be tied to that act.
Nick Green: Yes, I mean, very high level, Matt. I think, we obviously compete in that marketplace, and we compete against Asian competitors and Chinese competitors in particular on a regular day-to-day basis. I would say that, of the pipeline that we get from the numbers that we've managed to scratch through and be able to try to get some definition, about half of the ones that we see from China are probably BIOSECURE associated to date. There is an element of that. Some of them were -- the others that we've already won or have been in progress with were prior to any BIOSECURE conversation that they initiated. So I think it's fairly safe to say the other half wouldn't -- have nothing to do with that. How that builds up is going to be interesting. I think there are two fundamental elements is that while there is no definition about it, there's obviously concern and fear, so that can drive decision-making. Although I do think there's also, in the absence of the law, there's also people who feel that can we get in and out, or can we progress as we might do in the past, until it's more defined. So it's going to be interesting to see how that actually pans out. I mean, it's difficult to say that it's a bad thing for a U.S. based CDMO with capacity like we are. So it will be certainly interesting to see how that pans out over the near term.
Matthew Hewitt: Got it. And then second question, regarding seasonality, obviously, this is the quarter we're currently in is normally the quarter you're shut down and kind of going through some cleaning and all that. But given the newness of the facilities and the equipment, is it safe to expect that shutdown period will be lighter this year than you witnessed the last few years? And if that's the case, you just -- maybe that normal seasonality isn't as big of a deal this year. Is that -- am I thinking about that right?
Nick Green: I mean, in general terms, I think you are. What I would say for this year is, I wouldn't be looking at it that way right off the bat. We've just got the new facilities online, so we do still need to maintain those facilities. We still do need to do certain activities to make sure everything's up to date and any calibrations and things like that are all done. So we are trying a few things that we think we'll be able to in the longer term, reduce the scope of that shutdown. But I -- on the basis that it's our first year with the new facilities, I wouldn't be building in too much to that effect, if you know what I mean.
Matthew Hewitt: Got it. Understood. All right. Thank you.
Operator: Thank you. One moment for the next question. And our next question is coming from Paul Knight of KeyBanc Capital Markets. Your line is open.
Paul Knight: Hi, Nick. Were you -- did you spell out how much of the new orders, maybe Matt, were in the cell and gene therapy area?
Nick Green: A small proportion, Paul. We don't break that one out, but it's certainly not material in the overall scheme of things. So we don't segment those two just yet, but not enormous.
Paul Knight: You know, a company in the -- not kind of, kind of in the media market has said they expect a four-quarter lag on cell therapy funding. Do you think that's kind of in the ballpark?
Nick Green: I'm not sure. I go quite as far as four quarters. It depends on -- it's a difficult way to look at. We've seen some pickup. I think if I look, from looking back at the mammalian side, I think November was the low from end of October, the beginning of November was the low. So we're not gone full four quarters. I think, I've seen some pickup in certainly our activity in terms of the cell and gene therapy, but I wouldn't say it's accelerating at the level that we saw from November in the mammalian side. And even in the mammalian side, we are getting some sort of conflicting data. I think Charles River has indicated that they were seeing a reduction in the early phase. So I think it's coming through. I think I'd be probably a little more optimistic from what we've seen, but we're certainly no bellwether for the overall industry. So I'm not going to argue if somebody else sees it as four quarters, and we might see it at two or three, but that's where we are at the moment, I think.
Paul Knight: And Nick, you had previously indicated that sometimes the backlog now would extend beyond a year. I'm assuming that's still the case. But is it stretched even more in terms of duration of a project, or is it kind of similar to what you've been seeing?
Nick Green: No, I think that was kind of the crux of Sean's question at the beginning, was that -- I think the mix of the signings that we've got this quarter are a little richer in the early phase than traditionally. Still the majority of them are late phase, but there is a higher proportion than we are in a higher number of early phase than we had seen in the last two or three quarters of last year. So if anything, it's slightly accelerating it and maybe reducing it from 15 to a little bit less. But it's not material. But I would say, it's a definite not extending as it were.
Paul Knight: And then lastly, I know there's BIOSECURE here in the United States, but is there anything new on the regulatory front in Europe that puts you in a bit better of a position?
Nick Green: No. I mean, I heard some rumblings that people might believe in, that they may take similar actions in Europe. I haven't seen anything definitive that suggests that that's going to be the case. So really, all we have today, as far as I can see, in the immediate horizon is the BIOSECURE Act here in the U.S.
Paul Knight: Okay. Thanks.
Nick Green: Thanks, Paul.
Operator: Thank you. And one moment for the next question. And our next question will be coming from Max Smock of William Blair. Your line is open.
Max Smock: Hi, guys. Good afternoon. Thanks for taking our questions. To start just echo Sean's comments early and say congrats on the nice bookings quarter here in the first quarter. I wanted to ask a follow-up on Matt's question on BIOSECURE. It sounds like you have some customers that are still waiting to see, how it plays out before moving away from China. But is it fair to say that, most of the companies you're talking with are already committed to changing their behavior and moving away from China, kind of regardless of what happens with the bill here near term? And in your conversations, are you picking up on any material differences in terms of how small biotech and large pharma are currently reacting or planning to react to the BIOSECURE Act?
Nick Green: Good questions, Max. I think when people are talking to us, we obviously get, I guess, a more biased view of the impact of BIOSECURE. Because if you are in China and you're coming to Avid and you're talking to me about it, then that suggests that you've already caused a problem. So the person who isn't looking to move won't even call me, so I won't even hear their voice. So that one's always a little bit difficult to judge on the total pipeline of customers, are they -- what we're seeing, obviously, is thinking of moving or are moving. So I'm not sure, how much I would actually rely on that as a data point, but I think we've certainly seen an increasing number of conversations around that area. Big pharma to emerging pharma, I think it's not necessarily the easiest one. Again, I don't deal with all big pharma, but I would say that, we've seen interest in Avid. Is that interest in Avid more because they're looking at like getting rid of somebody else or looking at other alternatives that may be backups? It could well be. I think also it depends on what phase that you're in the biotech phase. I think if you're in early phase, then maybe there is the view that you could get in and out before that occurs, in which case then you could still source from that region or those people. In the case of the later phase, then that obviously becomes a little bit more concerning because you may have a regulatory filing that could get caught up in the outcome of whatever the outcome ends up being. So I think, I would see the larger concern from what we can see would be probably the later phase, clinical candidates that are probably getting more attention than anybody else. But I do hasten to point out that we are not the bellwether of the whole industry. So it's the microcosm that we see.
Max Smock: Yes. Fair enough. And thanks for that comment, Nick. A lot of good stuff in there. Maybe following up on an unrelated one, I wanted to ask about Halozyme, which obviously a key customer was over half your revenue in fiscal '23, but that was down to about a third in fiscal 2024. Can you just give us an update around what exactly happened there in fiscal 2023? How Halozyme revenues trended so far, or trended so far here in the first quarter? And kind of what you're baking in for Halozyme revenue here in fiscal 2025? And just your overall level of visibility into revenue this year from this key customer.
Nick Green: Yes. Again, I obviously do know, what went on between ourselves and Halozyme. I don't think any of it's negative in any way, shape or form. But I try to avoid commenting on somebody else's business, particularly in a public environment, in a public company, rather. So I think that I'll leave that one as is. But what I can say is that I think the relationship remains strong. I think that what's been going on over the last few years is nothing but positive. As far as I can see, we continue to be the best supplier we possibly can be and service that, as well as our other clients to the highest possible standard that we can. I've said it publicly in the past, I'd love to see the Halozyme revenues continue to grow, and I'd love to see them become a smaller proportion of our business as we continue to grow ourselves and diversify our customer base and we remain pretty much the same. So I think, what I would take out of the last year is that we're still growing compared to where we were over the last few years and it is becoming a smaller number over the long term. And that's, I think, in the direction that we've been articulating. And again, I just hope that we can continue to grow along with Halozyme.
Max Smock: Yes. Understood. And again, not necessarily a bad thing, right, I think it speaks to the strength of your -- the rest of your customer base there. Maybe, just sneaking a final one in here for me. Wanted to ask about the margins and just whether or not there is any color you can give us in terms of expectations for adjusted EBITDA or adjusted EBITDA margin here in fiscal 2025. And from a modeling perspective, is it reasonable to think about this quarter as kind of being a good jumping off point for the rest of the year and assuming something like that 40% to 60% drop through rate on incremental revenue that you pointed to in the past.
Dan Hart: Hi Max, good question. It was nice to see that we built off the momentum of where we were coming off of Q2 of last year, looking at Q3 and Q4 increases and we're seeing where we ended up for Q4 as far as fall through of overall gross margins right down to EBITDA margin, as we continue to grow in approach the guide for this year. I'd like to see EBITDA continue to grow, but as we always say, the quarters can be lumpy. So we will have some pluses and minuses as we grow. But I'd like to see something similar and continue to grow as we go forward.
Max Smock: Understood. Thanks again for taking our questions.
Nick Green: Thanks, Max.
Operator: Thank you. And that does conclude today's Q&A session. I would like to turn the call back over to Nick for closing remarks. Please go ahead.
Nick Green: Thank you, operator, and thank you to everyone participating on today's call. We are highly encouraged by the progress during the first quarter and we look ahead to the remainder of fiscal 2025 with some optimism. We thank our customers for their trust and partnership, our investors for their continued support and we wish to recognize the exceptional employees who continue to drive this success. Thank you again for participating today and for your continued support of Avid Bioservices.
Operator: This does conclude today's conference call. You may all disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.